NCT00545857

Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Stony Brook University · Academic / Other
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

A study to examine the effect of pioglitazone on the course of new onset type 1 diabetes mellitus.

Detailed description

Thiazolidinediones have been shown to reduce the development of diabetes mellitus in animal models of type 1 diabetes and to reduce the death of beta cells (cells that make insulin) in petri dishes. Pioglitazone is a thiazolidinedione currently approved for the treatment of type 2 diabetes. This study explores the question of whether pioglitazone can preserve beta cell function in patients with recently diagnosed type 1 diabetes mellitus.

Conditions

• Type 1 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	pioglitazone	Pioglitazone daily; dose varies with size
DRUG	Placebo control	Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus

Timeline

• Start date: 2002-06-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2007-10-17
• Last updated: 2012-05-31

Locations

1 site across 1 country: United States